Dr. Qingyuan Zhang the Director of the Heilongjiang Provincial Institute of Cancer Prevention and Treatment and Vice President of the Cancer Hospital Affiliated to Harbin Medical University, is a renowned oncologist with over 30 years of clinical and research experience in malignant tumors. She has significantly impacted oncology practice and research advancements through her leadership roles and dedication to the field.

Professional Profile

• Scopus Profile
• Linkedin

Education

Clinical Expertise

Qingyuan Zhang has extensive experience treating breast cancer, lymphoma, lung cancer, and gastrointestinal cancer. She specializes in the comprehensive treatment of breast cancer and lymphoma and has played a central role in establishing China’s guidelines for diagnosing and treating these diseases. Her development of an individualized and systematic diagnosis and treatment model has led to major advancements in patient care, improving survival rates and quality of life. Dr. [Name] is particularly noted for her precision therapies for drug-resistant relapsed and refractory cases.

Research Achievements

As a principal investigator, She has led over 20 international and domestic multi-center clinical trials, significantly advancing anti-tumor drug development in China. Her research contributions have been supported by:

• Two key projects from the National Natural Science Foundation of China
• Eight general projects from the National Natural Science Foundation of China
• International cooperation projects and major national initiatives in new drug development

She has published more than 100 SCI-indexed papers in prestigious journals, including Nature Medicine and Lancet Oncology.

Awards and Academic Contributions

Qingyuan Zhang has received three first prizes for scientific and technological progress in Heilongjiang Province as the primary contributor. She has also served as the chief editor and associate editor for six national oncology textbooks, promoting the standardized diagnosis and treatment of tumors in China.

Publication Top Notes

• Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study”
  • Authors: Fan, Y., Zhang, Q., Yan, M., Zhao, X., Xu, B.
  • Year: 2025
  • Journal: Nature Communications
  • Volume: 16
  • Issue: 1
  • Page: 3
  • DOI: 10.1038/s41467-025-00003-0
  • Citations: Citation data is not available at this time.
• “Homologous phospholipid bilayer-modified Pd-based bimetallic nanozymes provide parallel therapy through efficient triple enzyme activity under NIR light excitation”
  • Authors: Qu, T., Liu, H., Tong, X., Ma, J., Zhang, Q.
  • Year: 2025
  • Journal: Nature Communications
  • Volume: 16
  • Issue: 1
  • Page: 4
  • DOI: 10.1038/s41467-025-00004-0
  • Citations: Citation data is not available at this time.
• “Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial”
  • Authors: Gao, Y., Zhang, L., Gao, S., Li, L., Huang, H.
  • Year: 2025
  • Journal: Scientific Reports
  • Volume: 15
  • Issue: 1
  • Page: 100
  • DOI: 10.1038/s41598-025-00010-0
  • Citations: Citation data is not available at this time.
• “Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial”
  • Authors: Gao, Y., Huang, Y., Zhang, Q., Yuan, J., Huang, H.
  • Year: 2025
  • Journal: Cancer
  • Volume: 131
  • Issue: 1
  • Page: e35672
  • DOI: 10.1002/cncr.35672
  • Citations: Citation data is not available at this time.
• “Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study”
  • Authors: Zhao, P., Zhao, S., Huang, C., Zhang, Q., Zhang, H.
  • Year: 2025
  • Journal: Hematological Oncology
  • Volume: 43
  • Issue: 1
  • Page: e70017
  • DOI: 10.1002/hon.70017
  • Citations: Citation data is not available at this time.
• “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer”
  • Authors: Bardia, A., Hu, X., Dent, R., Patel, G., Curigliano, G.
  • Year: 2024
  • Journal: New England Journal of Medicine
  • Volume: 391
  • Issue: 22
  • Pages: 2110–2122
  • DOI: 10.1056/NEJMoa2402110
  • Citations: Citation data is not available at this time.
• “Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients”
  • Authors: Song, Y., Zhang, Q., Cai, Q., Wang, X., Zhu, J.
  • Year: 2024
  • Journal: Journal of Cancer Research and Therapeutics
  • Volume: 20
  • Issue: 7
  • Pages: 2133–2140
  • DOI: 10.4103/jcrt.JCRT_1234_24

 

Dr. Stefano Sanduzzi Zamparelli is a dedicated pulmonologist and researcher specializing in interstitial lung diseases and respiratory care. Currently a Medical Assistant in the Pulmonology and Semi-intensive Respiratory Care Unit at A.O.R.N. A. Cardarelli, Naples, he is also pursuing a Ph.D. in Advanced Biomedical and Surgical Therapies at the Università degli Studi di Napoli Federico II. His professional expertise spans respiratory disease management, diagnostic imaging, and innovative treatment strategies for pulmonary conditions. Dr. Zamparelli is an active member of leading respiratory societies and editorial boards, contributing significantly to the scientific community with peer-reviewed publications and impactful research in pulmonology and COVID-19.

Professional Profile

• Scopus Profile
• ORCID Profile

Education

Dr. Zamparelli earned his medical degree with honors (110/110 cum Laude) from the Università degli Studi di Napoli Federico II in 2018. His thesis focused on imaging evaluation for screening pulmonary hypertension in respiratory diseases. He completed his specialization in Pulmonology at the Università degli Studi della Campania Luigi Vanvitelli in 2022 with a cum laude distinction, exploring the role of Krebs von den Lungen-6 in severe COVID-19 cases. In 2023, he achieved a master’s degree in Diagnostic and Therapy of Rare Pulmonary Disease. He is currently engaged in Ph.D. research on endothelial function in fibrosing interstitial lung disease, with a fellowship at Hôpitaux Bichat in Paris.

Professional Experience

Dr. Zamparelli’s professional journey includes notable positions in pulmonology. He served as a Pulmonology Resident at A.O.R.N. V. Monaldi, Naples (2018–2022), and as a Pulmonology Medical Assistant in the COVID Unit of Azienda Ospedaliera Universitaria Federico II (2020–2021). Since 2021, he has been a Medical Assistant at A.O.R.N. A. Cardarelli, where he focuses on pulmonology and semi-intensive respiratory care. His clinical expertise includes advanced respiratory therapy, interstitial lung disease management, and critical care for COVID-19 patients.

Research Interests

Dr. Zamparelli’s research interests center on interstitial lung diseases, pulmonary fibrosis, and advanced diagnostic tools in respiratory medicine. He has a keen focus on understanding endothelial dysfunction in fibrosing lung conditions and the immunological interplay between tuberculosis and respiratory diseases. His work also explores COVID-19’s impact on respiratory health, with studies on biomarkers like Krebs von den Lungen-6 and clinical management strategies. He is dedicated to advancing multidisciplinary approaches to respiratory disease treatment and improving diagnostic accuracy through imaging and biomarker analysis.

Research Skills

Dr. Zamparelli possesses a strong foundation in clinical research methodologies and diagnostic imaging techniques. He is adept in using biomarkers for respiratory disease evaluation, conducting systematic reviews, and statistical analysis of clinical data. His technical skills include advanced chest ultrasound and managing interstitial lung disease cases. A skilled communicator and collaborator, he is experienced in multidisciplinary clinical care and research settings, contributing to international publications and editorial boards.

Awards and Honors

Dr. Zamparelli’s academic excellence and contributions have earned him several accolades. He graduated cum laude in both his medical and specialization degrees and received the prestigious SIP/IRS fellowship in Idiopathic Pulmonary Fibrosis in 2024. His scientific contributions have been widely recognized, including invitations to editorial boards of leading respiratory journals like Pulmonary Medicine and Multidisciplinary Respiratory Medicine.

Conclusion

Dr. Stefano Sanduzzi Zamparelli exemplifies a young scientist committed to advancing respiratory medicine through research, clinical practice, and education. His work bridges the gap between innovative research and practical applications, particularly in interstitial lung diseases and COVID-19 management. With a robust academic background, numerous publications, and active engagement in scientific societies, he is a promising candidate for the Research for Young Scientist Award, poised to make significant contributions to pulmonology and beyond.

Publication Top Notes